ANCA-associated Vasculitis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Amgen, GlaxoSmithKline, AstraZeneca, Chemocentryx, Staidson (Beijing) Biopharma, Novartis, NovelMed

The Key ANCA-associated Vasculitis Companies in the market include - Chemocentryx, Amgen, GlaxoSmithKline, AstraZeneca, Staidson (Beijing) Biopharmaceuticals, Novartis, NovelMed Therapeutics, University of Edinburgh, Alpine Immune Sciences, Inc., Alentis Therapeutics AG, and others.

DelveInsight's "ANCA-associated Vasculitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the ANCA-associated Vasculitis, historical and forecasted epidemiology as well as the ANCA-associated Vasculitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the ANCA-associated Vasculitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ANCA-associated Vasculitis Market Forecast [https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the ANCA-associated Vasculitis Market Report:

*
The AAV market size was valued approximately USD 1500 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In March 2025, A Phase 1 clinical trial evaluating SC291, an experimental CAR T-cell therapy developed by Sana Biotechnology for ANCA-associated vasculitis (AAV) and other autoimmune conditions, is currently recruiting patients at multiple locations across the U.S. Named GLEAM (NCT06294236), the study began enrolling up to 36 adults, aged 18-75, last year at two sites: one in Aurora, Colorado, and the other in Seattle. Since then, three additional sites have opened in Atlanta, Baltimore, and Boston.

*
In January 2025, Lixudebart (ALE.F02), an investigational treatment being developed by Alentis Therapeutics to protect kidney health in ANCA-associated vasculitis (AAV), demonstrated a positive safety profile in a Phase 2 clinical trial, according to the company. In a separate study evaluating lixudebart in patients with liver disease, the therapy also exhibited a strong safety profile. Both trials indicate that lixudebart is functioning as expected.

*
In August 2024, Conduit Pharmaceuticals is preparing to initiate Phase 2a clinical trials for its lead oral drug, AZD1656, targeting immune system disorders, including ANCA-associated vasculitis (AAV) as one of the indications. With its potential to be a first-in-class treatment for autoimmune diseases, AZD1656 marks a significant advancement in the company's goal to develop innovative therapies that could revolutionize autoimmune care and offer meaningful solutions for patients.

*
In the 7MM countries, TAVNEOS (avacopan) is anticipated to yield the highest revenue, exceeding USD 1 billion by 2034.

*
According to DelveInsight's projections, approximately 214,800 diagnosed prevalent cases of ANCA-associated vasculitis (AAV) were reported across the seven major markets (7MM) in 2023. The United States had the largest share of cases in this group, with Japan following closely behind.

*
For patients experiencing relapsing or refractory disease, those unresponsive to treatments like cyclophosphamide or glucocorticoids may be prescribed rituximab, NUCALA (for GPA/MPA), and TAVNEOS (for EGPA).

*
Among emerging treatments like FASENRA (benralizumab) and GSK3511294 (depemokimab), FASENRA is projected to generate higher revenue than other therapies.

*
Key ANCA-associated Vasculitis Companies: Chemocentryx, Amgen, GlaxoSmithKline, AstraZeneca, Staidson (Beijing) Biopharmaceuticals, Novartis, NovelMed Therapeutics, University of Edinburgh, Alpine Immune Sciences, Inc., Alentis Therapeutics AG, and others

*
Key ANCA-associated Vasculitis Therapies: TAVNEOS (avacopan), Depemokimab (GSK3511294), FASENRA (benralizumab), BDB-001 injection, Avacopan, Iptacopan, NM8074, Sparsentan, povetacicept, Rituximab, and others

*
The ANCA-associated Vasculitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage ANCA-associated Vasculitis pipeline products will significantly revolutionize the ANCA-associated Vasculitis market dynamics.

ANCA-associated Vasculitis Overview

ANCA-associated vasculitis (AAV) is a group of autoimmune diseases that cause inflammation of blood vessels, leading to damage in various organs, including the kidneys, lungs, and upper respiratory tract. The condition is characterized by the presence of antineutrophil cytoplasmic antibodies (ANCA) in the blood, which target and attack certain white blood cells, causing vessel inflammation. AAV includes conditions like granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Symptoms often include fatigue, fever, weight loss, and organ-specific signs depending on the affected area. Treatment usually involves immunosuppressive drugs to reduce inflammation and manage symptoms

Get a Free sample for the ANCA-associated Vasculitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market [https://www.delveinsight.com/report-store/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

ANCA-associated Vasculitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

ANCA-associated Vasculitis Epidemiology Segmentation:

The ANCA-associated Vasculitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of ANCA-associated Vasculitis

*
Prevalent Cases of ANCA-associated Vasculitis by severity

*
Gender-specific Prevalence of ANCA-associated Vasculitis

*
Diagnosed Cases of Episodic and Chronic ANCA-associated Vasculitis

Download the report to understand which factors are driving ANCA-associated Vasculitis epidemiology trends @ ANCA-associated Vasculitis Epidemiology Forecast [https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

ANCA-associated Vasculitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ANCA-associated Vasculitis market or expected to get launched during the study period. The analysis covers ANCA-associated Vasculitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the ANCA-associated Vasculitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

ANCA-associated Vasculitis Therapies and Key Companies

*
TAVNEOS (avacopan): Chemocentryx/Amgen

*
Depemokimab (GSK3511294): GlaxoSmithKline

*
FASENRA (benralizumab): AstraZeneca

*
BDB-001 injection: Staidson (Beijing) Biopharmaceuticals

*
Avacopan: Amgen

*
Iptacopan: Novartis

*
NM8074: NovelMed Therapeutics

*
Sparsentan: University of Edinburgh

*
povetacicept: Alpine Immune Sciences, Inc.

*
Rituximab: Alentis Therapeutics AG

Discover more about therapies set to grab major ANCA-associated Vasculitis market share @ ANCA-associated Vasculitis Treatment Landscape [https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the ANCA-associated Vasculitis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key ANCA-associated Vasculitis Companies: Chemocentryx, Amgen, GlaxoSmithKline, AstraZeneca, Staidson (Beijing) Biopharmaceuticals, Novartis, NovelMed Therapeutics, University of Edinburgh, Alpine Immune Sciences, Inc., Alentis Therapeutics AG, and others

*
Key ANCA-associated Vasculitis Therapies: TAVNEOS (avacopan), Depemokimab (GSK3511294), FASENRA (benralizumab), BDB-001 injection, Avacopan, Iptacopan, NM8074, Sparsentan, povetacicept, Rituximab, and others

*
ANCA-associated Vasculitis Therapeutic Assessment: ANCA-associated Vasculitis current marketed and ANCA-associated Vasculitis emerging therapies

*
ANCA-associated Vasculitis Market Dynamics: ANCA-associated Vasculitis market drivers and ANCA-associated Vasculitis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
ANCA-associated Vasculitis Unmet Needs, KOL's views, Analyst's views, ANCA-associated Vasculitis Market Access and Reimbursement

To know more about ANCA-associated Vasculitis companies working in the treatment market, visit @ ANCA-associated Vasculitis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. ANCA-associated Vasculitis Market Report Introduction

2. Executive Summary for ANCA-associated Vasculitis

3. SWOT analysis of ANCA-associated Vasculitis

4. ANCA-associated Vasculitis Patient Share (%) Overview at a Glance

5. ANCA-associated Vasculitis Market Overview at a Glance

6. ANCA-associated Vasculitis Disease Background and Overview

7. ANCA-associated Vasculitis Epidemiology and Patient Population

8. Country-Specific Patient Population of ANCA-associated Vasculitis

9. ANCA-associated Vasculitis Current Treatment and Medical Practices

10. ANCA-associated Vasculitis Unmet Needs

11. ANCA-associated Vasculitis Emerging Therapies

12. ANCA-associated Vasculitis Market Outlook

13. Country-Wise ANCA-associated Vasculitis Market Analysis (2020-2034)

14. ANCA-associated Vasculitis Market Access and Reimbursement of Therapies

15. ANCA-associated Vasculitis Market Drivers

16. ANCA-associated Vasculitis Market Barriers

17. ANCA-associated Vasculitis Appendix

18. ANCA-associated Vasculitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ancaassociated-vasculitis-market-to-reach-new-heights-in-growth-by-2034-delveinsight-predicts-amgen-glaxosmithkline-astrazeneca-chemocentryx-staidson-beijing-biopharma-novartis-novelmed]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.